301 related articles for article (PubMed ID: 25023700)
21. OGG1 co-inhibition antagonizes the tumor-inhibitory effects of targeting MTH1.
Zhang L; Misiara L; Samaranayake GJ; Sharma N; Nguyen DM; Tahara YK; Kool ET; Rai P
Redox Biol; 2021 Apr; 40():101848. PubMed ID: 33450725
[TBL] [Abstract][Full Text] [Related]
22. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
Sato M; Larsen JE; Lee W; Sun H; Shames DS; Dalvi MP; Ramirez RD; Tang H; DiMaio JM; Gao B; Xie Y; Wistuba II; Gazdar AF; Shay JW; Minna JD
Mol Cancer Res; 2013 Jun; 11(6):638-50. PubMed ID: 23449933
[TBL] [Abstract][Full Text] [Related]
23. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
24. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
25. The genetics and biology of KRAS in lung cancer.
Westcott PM; To MD
Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
[TBL] [Abstract][Full Text] [Related]
26. Selective activation of p53-mediated tumour suppression in high-grade tumours.
Junttila MR; Karnezis AN; Garcia D; Madriles F; Kortlever RM; Rostker F; Brown Swigart L; Pham DM; Seo Y; Evan GI; Martins CP
Nature; 2010 Nov; 468(7323):567-71. PubMed ID: 21107427
[TBL] [Abstract][Full Text] [Related]
27. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
Moran DM; Trusk PB; Pry K; Paz K; Sidransky D; Bacus SS
Mol Cancer Ther; 2014 Jun; 13(6):1611-24. PubMed ID: 24688052
[TBL] [Abstract][Full Text] [Related]
28. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
Vandal G; Geiling B; Dankort D
PLoS One; 2014; 9(1):e84745. PubMed ID: 24489653
[TBL] [Abstract][Full Text] [Related]
29. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
Volonte D; Vyas AR; Chen C; Dacic S; Stabile LP; Kurland BF; Abberbock SR; Burns TF; Herman JG; Di YP; Galbiati F
J Biol Chem; 2018 Feb; 293(5):1794-1809. PubMed ID: 29247004
[TBL] [Abstract][Full Text] [Related]
30. WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.
Wu C; Wang S; Xu C; Tyler A; Li X; Andersson C; Oji Y; Sugiyama H; Chen Y; Li A
Cell Physiol Biochem; 2015; 35(2):647-62. PubMed ID: 25613309
[TBL] [Abstract][Full Text] [Related]
31. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
32. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
33. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.
Liang H; Zhang J; Shao C; Zhao L; Xu W; Sutherland LC; Wang K
J Exp Clin Cancer Res; 2012 Apr; 31(1):36. PubMed ID: 22537942
[TBL] [Abstract][Full Text] [Related]
35. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
[TBL] [Abstract][Full Text] [Related]
36. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
Okudela K; Yazawa T; Woo T; Sakaeda M; Ishii J; Mitsui H; Shimoyamada H; Sato H; Tajiri M; Ogawa N; Masuda M; Takahashi T; Sugimura H; Kitamura H
Am J Pathol; 2009 Aug; 175(2):867-81. PubMed ID: 19608870
[TBL] [Abstract][Full Text] [Related]
38. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.
Meyer SE; Hasenstein JR; Baktula A; Velu CS; Xu Y; Wan H; Whitsett JA; Gilks CB; Grimes HL
Am J Pathol; 2010 Sep; 177(3):1503-13. PubMed ID: 20639455
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].
Han C; Zou H; Ma J; Zhou Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):882-91. PubMed ID: 20840818
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of MutT homolog-1 expression on esophageal squamous cell carcinoma.
Akiyama S; Saeki H; Nakashima Y; Iimori M; Kitao H; Oki E; Oda Y; Nakabeppu Y; Kakeji Y; Maehara Y
Cancer Med; 2017 Jan; 6(1):258-266. PubMed ID: 27917618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
